Jasper Therapeutics, Inc.
JSPRJasper Therapeutics is a clinical-stage biotechnology company dedicated to developing monoclonal antibody therapies for mast cell-driven diseases.
Earnings
Next report
Nov 9, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Jasper Therapeutics is a clinical-stage biotechnology company dedicated to developing monoclonal antibody therapies for mast cell-driven diseases. The company's core value proposition centers on its lead product candidate, briquilimab, which targets the SCF/KIT pathway to deplete mast cells and address underlying disease biology in chronic inflammatory conditions. Jasper aims to transition into a fully integrated discovery, development, and commercial organization focused on immune modulation.
A clinical-stage developer with exclusive global rights to a high-affinity KIT-targeted monoclonal antibody designed for mast cell depletion.
FAQ
- What is Jasper Therapeutics, Inc.'s market cap?
- Jasper Therapeutics, Inc. (JSPR) has a market capitalization of $17.7M and trades on NASDAQ.
- Who are Jasper Therapeutics, Inc.'s competitors?
- Jasper Therapeutics, Inc.'s key competitors include Celldex Therapeutics, Inc., Jade Biosciences, Inc. Common Stock, Shattuck Labs, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Jasper Therapeutics, Inc. partner with?
- Jasper Therapeutics, Inc.'s notable partners include Amgen Inc., Stanford University, Lonza Sales AG, and others.
- What subsidiaries does Jasper Therapeutics, Inc. have?
- Jasper Therapeutics, Inc.'s subsidiaries include Jasper Tx Corp..
- Where is Jasper Therapeutics, Inc. headquartered?
- Jasper Therapeutics, Inc. is headquartered in United States of America and employs approximately 45 people. It has been publicly traded since 2021.